Misplaced Pages

This is an old revision of this page, as edited by Boghog (talk | contribs) at 19:40, 18 December 2024 (ce). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Vamicamide

Clinical data
Other names	Urocut, FK-176
Identifiers
IUPAC name (2R,4R)-4-(dimethylamino)-2-phenyl-2-pyridin-2-ylpentanamide
CAS Number	132373-81-0
PubChem CID	65967
ChemSpider	59369
Chemical and physical data
Formula	C18H23N3O
Molar mass	297.402 g·mol
3D model (JSmol)	Interactive image
SMILES C(C(C1=CC=CC=C1)(C2=CC=CC=N2)C(=O)N)N(C)C
InChI InChI=1S/C18H23N3O/c1-14(21(2)3)13-18(17(19)22,15-9-5-4-6-10-15)16-11-7-8-12-20-16/h4-12,14H,13H2,1-3H3,(H2,19,22)/t14-,18-/m1/s1 Key:BWNLUIXQIHPUGO-RDTXWAMCSA-N

Vamicamide, also known as FK-176 or Urocut, is a muscarinic acetylcholine receptor (mAChR) antagonist that was developed by Fujisawa (now part of Astellas Pharma) for the treatment of urinary incontinence and overactive bladder. This small molecule drug acts by blocking muscarinic receptors, which play a role in bladder function. Despite showing promise in preclinical studies for increasing bladder capacity without affecting other urinary parameters, vamicamide has never been approved for medical use. The drug's development was ultimately discontinued, with its highest research and development status reaching the New Drug Application (NDA) phase in Japan.

References

1. ^ "Vamicamide". PatSnap.
2. Yamamoto T, Koibuchi Y, Miura S, Sawada T, Ozaki R, Esumi K, Ohtsuka M (December 1995). "Effects of vamicamide on urinary bladder functions in conscious dog and rat models of urinary frequency". The Journal of Urology. 154 (6): 2174–8. PMID 7500484.

• Muscarinic antagonists